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Abstract: Irreversible disability in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder
(NMOSD) is largely attributed to neuronal and axonal degeneration, which, along with inflammation,
is one of the major pathological hallmarks of these diseases. Optical coherence tomography (OCT)
is a non-invasive imaging tool that has been used in MS, NMOSD, and other diseases to quantify
damage to the retina, including the ganglion cells and their axons. The fact that these are the
only unmyelinated axons within the central nervous system (CNS) renders the afferent visual
pathway an ideal model for studying axonal and neuronal degeneration in neurodegenerative
diseases. Structural magnetic resonance imaging (MRI) can be used to obtain anatomical information
about the CNS and to quantify evolving pathology in MS and NMOSD, both globally and in specific
regions of the visual pathway including the optic nerve, optic radiations and visual cortex. Therefore,
correlations between brain or optic nerve abnormalities on MRI, and retinal pathology using OCT,
may shed light on how damage to one part of the CNS can affect others. In addition, these imaging
techniques can help identify important differences between MS and NMOSD such as disease-specific
damage to the visual pathway, trans-synaptic degeneration, or pathological changes independent
of the underlying disease process. This review focuses on the current knowledge of the role of the
visual pathway using OCT and MRI in patients with MS and NMOSD. Emphasis is placed on studies
that employ both MRI and OCT to investigate damage to the visual system in these diseases.
Keywords: multiple sclerosis; neuromyelitis optica spectrum disorder; optical coherence tomography;
magnetic resonance imaging; optic neuritis; visual pathway; optic nerve; optic radiations;
visual cortex
1. Introduction
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disorder of the central nervous
system (CNS) in which different environmental factors act on the basis of a multi-genetic trait [1,2]. It is
characterized by focal demyelinating plaques and diffuse neurodegeneration throughout the white
and gray matter [3,4]. Approximately two million people worldwide are affected by this disorder, and
it is the most common non-traumatic neurological disability affecting young adults [5]. Neuromyelitis
optica spectrum disorder (NMOSD) is a rare autoimmune astrocytopathic disease of the CNS that
preferentially involves the optic nerve and spinal cord [6,7]. The identification of the disease-specific
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NMO-immunoglobulin G (NMO-IgG) and its effects on astrocytic aquaporin-4 (AQP4) water channels
has helped to facilitate differentiation of NMOSD from MS [8]. Nevertheless, imaging and clinical
manifestations frequently overlap, particularly in the early stages of the diseases and in NMOSD
patients testing negative for AQP4-IgG antibodies [7]. The exact pathophysiological mechanisms
behind MS and NMOSD have still not been fully elucidated; however, there is evidence that tissue
injury and demyelination in MS is mediated by T-cell activity [9]. Axonal and neuronal atrophy is
likely a secondary effect of inflammatory demyelination but can also occur as a result of independent
subclinical disease activity [9]. Neuro-axonal degeneration (in addition to demyelination) has recently
been considered more relevant in MS pathophysiology; it has been documented in both active and
inactive lesions, distal to the areas affected by autoimmune inflammation, and early in the disease
course [10]. Conversely, the pathophysiology in NMOSD predominantly involves the deposition of
IgG and complement, resulting in a loss of AQP4 proteins on astrocytes and severe neuronal and
axonal loss [6].
Both diseases present with significant clinical and pathological heterogeneity between individuals.
However, visual impairment appears to be prominent in both disorders, with acute optic neuritis (ON)
frequently occurring as the initial symptom [11,12]. ON is an inflammation of the optic nerve that
is usually accompanied by pain on eye movement followed by visual loss [13]. Recovery of visual
function is often incomplete, likely due to persistent demyelination and—in more severe cases—axonal
loss [13]. ON is typically more severe, recurrent, and frequently bilateral in NMOSD compared to
MS [14,15].
Optical coherence tomography (OCT) is a safe and non-invasive 3D imaging tool that uses low
coherent, near-infrared light to generate cross-sectional images of the retina, which can be used to
quantify axonal and neuronal atrophy [16]. Three-dimensional volumetric scans can be formed from
multiple cross-sectional images of the retina and, with contemporary spectral-domain OCT (SD-OCT)
devices, identification and delineation (”segmentation”) of the individual layers is now possible.
SD-OCT is more reproducible, faster and has better resolution than previous time-domain (TD-OCT)
devices [17].
When examining the retina, numerous studies have demonstrated peripapillary retinal nerve
fiber layer (RNFL) thinning and decreased total macular volume (TMV) in NMOSD and MS, and
this thinning is more prominent in patients with a history of ON but is also observed in those
without [18–21]. RNFL thinning reflects damage to unmyelinated ganglion cell axons and may
be due to ON-related retrograde degeneration (damage propagating backwards from the site of
injury). Interestingly, structural damage to the retina can occur with or without the presence of ON in
both MS and NMOSD. A previous study found thinning of the ganglion cell layer (GCL) and inner
plexiform layer (IPL) in patients with clinically isolated syndrome (CIS), suggesting that not only is
neurodegeneration a prominent component of MS pathology, but that it can occur early in the disease
course [22]. The damage seen in eyes without a history of ON is likely due to subclinical disease
activity, which is commonly identified in MS but has only recently been reported in NMOSD. It is
possible that in NMOSD, Müller cells (which span the entire thickness of the retina and contain an
abundance of AQP4 channels; Figure 1) may be affected in patients without ON history [23], although
this remains unconfirmed [20]. Moreover, lesions in other parts of the visual pathway may have
affected the retina via retrograde degeneration. Macular RNFL is less commonly studied compared to
peripapillary RNFL but appears to be thinner in MS patients with or without a history of ON compared
to healthy controls [24].
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Figure 1. The different layers and cells that make up the retina. Retinal nerve fiber layer (RNFL),
ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer
(OPL), and outer nuclear layer (ONL), and photoreceptor layer (PR).
GCL and IPL thinning have been observed in both MS and NMOSD; in particular, NMOSD
patients typically exhibit thinner GCL and IPL compared to MS patients [23,25], most likely reflecting
more severe neuronal and axonal involvement in NMOSD [26]. It is likely that retrograde degeneration
begins at the ganglion cell axons (RNFL), progresses to the cell bodies (located in the GCL) and then to
the dendrites (located in the IPL), where degeneration appears to stop (Figure 1) [25,27].
Inner nuclear layer (INL) thickness is associated with inflammatory disease activity in MS [28].
While INL thinning has been documented in a minority of MS patients [29], INL thickening has been
observed more frequently [20,30,31] and seems to have the potential to differentiate between MS and
NMOSD [24]. INL thickening is often associated with microcystic macular edema (MME) [20,31] but
can also occur independently of MME [30]. MME is the finding of intra-retinal cyst-like spaces in the
INL [32,33]. It is thought to result from the breakdown of the blood-retinal barrier with or without
microglial inflammation and subsequent accumulation of fluid within the retina [33], but it has also
been suggested to be due to impaired water or potassium homeostasis [32]. The outer nuclear layer
(ONL) contains the cell bodies of rods and cones; previous studies have found no significant differences
in ONL thickness between healthy controls and MS [25,34] or NMOSD [20] patients.
Magnetic resonance imaging (MRI) is a valuable tool used for identifying, characterizing and
quantifying CNS pathology in MS and NMOSD [35]. It is a reproducible and sensitive method with the
advantage of being able to obtain measurements from the entire brain and spinal column. Unlike in MS,
NMOSD was previously thought to feature no brain involvement; however, it is now well-established
that development of non-specific brain lesions can also occur in NMOSD [36].
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Conventional imaging techniques are commonly used to monitor disease activity by quantifying
lesion load (lesion number and volume on T2- or gadolinium enhanced T1-weighted images) and,
more recently, neurodegeneration, through the measurement of global brain volume loss (based on
anatomical T1 and T2/FLAIR data), frequently referred to as brain atrophy. Brain volume loss can
be assessed either cross-sectionally, using brain parenchymal fraction (BPF), or longitudinally, using
registration-based approaches such as SIENA (Structural Image Evaluation, using Normalization,
of Atrophy) [37], to reflect tissue atrophy caused by both demyelination and axonal loss [38–40].
While lesion detection and qualitative assessments with conventional imaging techniques are used
in clinical practice for diagnosis and monitoring, this approach lacks pathological specificity and is
therefore unsuitable for characterizing the biological mechanisms and temporal sequences underlying
inflammatory demyelination and neuro-axonal degeneration in MS and NMOSD [41]. Further difficulty
arises from the fact that the complex pathological processes largely differ between MS and NMOSD in
a manner that has yet to be fully characterized [42,43].
In contrast, advanced MRI techniques may provide a more quantitative and potentially more
sensitive tool to detect subtle changes in the normal appearing white or gray matter (NAWM/NAGM),
which are often undetectable by conventional MRI sequences [43]. Magnetic resonance spectroscopy
(MRS), for example, can record signals from metabolites like N-acetylaspartate (NAA), which is
associated with axonal integrity and demyelination [44,45]. Myelin water imaging (MWI) and
magnetization transfer imaging (MTI) provide a sensitive in vivo measurement of myelin water
and macromolecule content within the CNS, respectively, whilst diffusion tensor imaging (DTI)
can be used to examine the integrity of the neural tracts [46–48]. DTI is the most commonly
used technique for examining the visual pathway, particularly the optic nerves, chiasm and optic
radiations [49,50]. Nevertheless, both conventional and advanced MRI techniques can provide
complementary information about the visual pathway.
OCT and MRI can be used to reliably monitor neurodegeneration in experimental models of
MS such as myelin oligodendrocyte glycoprotein (MOG) peptide induced experimental autoimmune
encephalomyelitis (EAE), a common MS model in rodents. Retinal changes have been detected
longitudinally with OCT and histo-morphological measurements, both before clinical manifestation,
and also during the disease course in MOG induced EAE rats [51]. Deterioration of the RNFL, GCL
and IPL has similarly been observed in MOG-EAE mice with ON, indicating a significant loss of retinal
ganglion cells over time [52]. Additionally, the visual pathway is selectively affected in MOG-EAE mice,
with both axonal and myelin injury observed using diffusion MRI and immunohistochemistry [53–55].
Studies combining OCT and MRI as tools for investigating the visual system in murine models of MS
are scarce, and have yet to be conducted with SD-OCT [56]. Therefore, this review will primarily focus
on human studies involving OCT and MRI.
Researchers have recently begun to explore the relationship between OCT-derived measures
of retinal layer thickness changes and MRI-derived brain volume loss in order to understand the
propagation of neuronal and axonal dysfunction throughout the CNS. These tools can be used to study
how damage to one part of the CNS may affect others, and to investigate the role of retrograde and
anterograde degeneration in the visual pathway. The objective of this manuscript is to provide an
extensive review of the current literature examining the relationships between OCT and MRI measures
in both MS and NMOSD.
2. Global Brain Measurements
A positive correlation between BPF, RNFL thickness and TMV was observed in a cohort of
MS patients with and without a history of ON [40,57]. This relationship suggests the presence
of widespread neurodegeneration in the CNS of MS patients, including the brain and optic nerve
(Figure 2). Another index of brain atrophy, bicaudate ratio, was also correlated with RNFL thickness
in MS patients [58]. Furthermore, a prospective study in early MS found an inverse correlation with
BPF and white matter fraction—but not with gray matter fraction—compared to RNFL thickness and
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TMV [10]. The existing gray matter association appeared to be due to an age-related effect, suggesting
that gray matter atrophy may not be prominent in early MS [10]. This is further supported by data from
MS patients with greater disability and longer disease duration, in whom an association between RNFL
and normalized gray and white matter volume in eyes with or without ON history was found [59].
Interestingly, there was an association between normalized brain, gray matter and white matter volume
and TMV, in MS eyes without a history of ON, but only in normalized white matter volume for eyes
with a history of ON [59]. The apparent discrepancy with regard to TMV may be because TMV reflects
the integrity of numerous distinct layers of the retina, both neuronal and axonal, and as such can only
provide a non-specific measure of retinal atrophy.
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Figure 2. OCT-derived peripapillary RNFL and macular GCL thickness (µm) for the right eye of a
healthy control, MS and NMOSD patients. (A) Peripapillary RNFL average thickness (µm) for each
quadrant. Green = RNFL thickness between the 95th and 5th percentile of a built-in normative database,
Yellow = RNFL thickness between the 5th and 1st percentile, Red = RNFL thickness less than the 1st
percentile; (B) Macular GCL thickness (µm) map; and (C) macular GCL average thickness (µm; in black)
and volume (mm3; in ed) fo e ch quadrant. OCT = optical coherence omography RNFL = retinal
nerve fiber layer, GCL = ganglion cell layer, MS = multiple sclerosis, NMOSD = neuromyelitis optica
spectrum disorder, T = temporal, S = superior, N = nasal, I = inferior, G = global, PMB = papillomacular
bundle, N/T = nasal:temporal ratio.
In MS eyes with and without a history of ON, there was a correlation between normalized
brain volum , white matter volume and GCL [59]. Other studies found that the peripapillary RNFL,
GCL-IPL, and INL thickness was associated with normalized gray and white matt r v lume only
in MS p tients without prior ON history [60,61]. In many studi s, GCL and IPL are frequently
aggregated for analysis (GCL-IPL) due to difficulty in accurately distinguishing the two layers visually
and with OCT segmentation tools [62]. Retinal damage seen outside the context of ON history may
be due to the diffuse effects of the disease throughout the CNS or due to atrophy in other parts of
the visual system (via retrograde degeneration). This also suggests that gray matter in the CNS is
comparable to the neuronal components of the retinal GCL [25,61]. However, it is possible that gray
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matter relationships are clouded by the presence of white matter atrophy caused by ON. In primary
progressive MS (PPMS), peripapillary RNFL thickness was associated with NAWM volume [61].
Interestingly, there was no relationship between RNFL thickness and NAA concentration, measured
with MRS in PPMS NAWM [57]. The relationships seen with global atrophy measures raise the
possibility that trans-synaptic degeneration is not restricted to the visual pathway, but is rather a
pathological phenomenon that disseminates throughout the MS brain.
An increased rate of thinning in GCL-IPL was correlated with increased rate of cortical gray,
cortical white, or whole brain atrophy [28]. The relationship between cerebral volume fraction
(a measure of whole brain atrophy) and the rate of GCL-IPL thinning was seen in all the MS subtypes,
however, a stronger relationship was seen in progressive MS subtypes compared to relapsing-remitting
MS (RRMS) [28]. Additionally, the rate of change in GCL-IPL thickness was related to the rate
of fluid-attenuated inversion recovery (FLAIR)-lesion volume accumulation in RRMS patients [28].
The rate of thinning in GCL-IPL appears to reflect global neurodegeneration and is linked to new
disease activity or disease progression; it may also be superior as a method of tracking degeneration
over time compared to the rate of thinning in the peripapillary RNFL [28].
RNFL and TMV did not correlate with either T2 hyper-intense lesion volume or T1 hypo-intense
lesion (‘black hole’) volume, both of which are non-specific markers for disease activity in MS [10,63].
In RRMS, INL thickness in eyes without prior ON was also associated with lesion volume [61].
The association between these OCT measures and lesion volume suggests that the mechanisms
involved in retinal pathology of these layers may be primarily inflammatory [61]. Additionally, the
rate of change in GCL-IPL and INL thickness was related to the rate of lesion volume accumulation
in RRMS patients [28]. Interestingly, the same authors had previously found that increased baseline
INL thickness was associated with a greater chance of developing new lesions and also predicted
the development of relapses and disability progression in MS [64]. They suggested that the observed
increase in INL thickness seen in previous studies might represent inflammatory activity in MS and
that INL thickness would decline over time [28]. Monitoring INL changes in RRMS may provide
important information on global inflammation longitudinally.
Intracranial volume (ICV) was correlated with GCL-IPL and ONL but not with INL, peripapillary
or macular RNFL thickness in MS [61]. There was a relationship observed in healthy controls for
all three OCT measures compared to ICV [61]. The authors suggest that this provides support for a
biological relationship between ICV and OCT thickness measures [61].
A lack of standardization in terms of statistical analysis and OCT scan protocols makes it difficult
to compare results between studies. In particular, potential concerns arise when comparing OCT
results with MRI findings. As visual information from each retina is conveyed to both sides of the brain,
it is currently not possible to correlate whole-brain-derived MRI data with OCT data from individual
eyes. An additional consideration is that both eyes of an individual patient are correlated to some
degree, and therefore consideration of intra-patient inter-eye dependencies is vital when analyzing or
modelling OCT results [10].
3. Optic Nerve
The optic nerve is a frequent site of injury in both MS and NMOSD and can be used to study
both axonal and neuronal degeneration in these diseases. When comparing OCT data to measures
of atrophy in the optic nerve obtained with fast spin echo MRI, a strong positive correlation was
seen with peripapillary RNFL thickness in MS patients [65]. A decrease in both the optic nerve lesion
magnetization transfer ratio (MTR) and entire optic nerve MTR correlated with RNFL thinning and
reduced TMV in a cohort including early MS and CIS patients [66]. Similarly, abnormal DTI was
positively associated with RNFL thinning in the optic nerves of patients with MS [49,67], in MS patients
with a history of ON [67] and also in a cohort including MS, NMOSD, and CIS [68]. This suggests that
axonal loss may be a pathological contributor to both MTI and DTI abnormalities. In a longitudinal
DTI study, reduced axial diffusivity (evidence of axonal fragmentation) in the optic nerve one month
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after ON was positively correlated with RNFL thickness in the affected eyes of CIS and early MS
patients at both 6 and 12 months after ON [69]. This indicates that axial diffusivity of the optic nerve
may be predictive of axonal damage in the retina that occurs in the months after an ON episode [69].
During the chronic phase of NMOSD, peripapillary RNFL was significantly associated with ON lesion
length [70]. Acute inflammatory lesions can result in physical or functional axonal damage to fibers
passing through the optic nerve lesions and, via retrograde degeneration, axonal loss could continue
onto distal regions such as the retina.
A negative correlation was observed between GCL-IPL thickness and the length of optic nerve
lesions one to two months following the onset of ON episodes [71]. These results suggest that atrophy
of the retinal ganglion cells may be greater in cases with longer lesions in the optic nerve [71]. However,
there was no relationship between proximity of lesions to the retina and GCL-IPL thinning, which
could suggest the involvement of factors other than retrograde degeneration [71].
TMV is also positively correlated with the area of the optic nerve lesions in MS patients [65]
and with DTI measures of axial and radial diffusivity in MS patients without a history of ON [67].
Interestingly, in MS patients with a history of ON, TMV was correlated with increased radial diffusivity
(an indicator of demyelination) but not with axial diffusivity [67]. The relationship between decreased
TMV and optic nerve damage is thought to be due to retrograde degeneration extending throughout
the entire retina [65].
4. Optic Tract
The optic tract is the post-chiasmal, pre-geniculate part of the visual pathway that includes the
most distal portion of the retinal ganglion cells axons. Due to the hemidecussation of axons in the
chiasm, lesions in the optic tract result in retrograde degeneration to the retina and will likely affect
both eyes [50,72]. However, in contrast to the optic nerve, lesions in the optic tract appear to be rare
in MS [72–74] and their incidence has to date not been fully explored in NMOSD. Nevertheless, the
possibility of subclinical disease activity in this area cannot be completely dismissed, as post-mortem
data suggest that axonal degeneration is present in the optic tract of MS patients [75]. Even without
the presence of lesions in the optic tract, DTI abnormalities have been found to correlate with RNFL
thinning and TMV reduction [39,73]. Additionally, peripapillary RNFL thickness in the temporal
quadrant correlated with DTI abnormalities in the ipsilateral optic tract; there appears to be an even
stronger relationship between these anatomically connected structures because the ipsilateral optic
tract receives input from the temporal quadrant [73]. This suggests that subclinical changes can occur
even in the absence of conventional MRI lesions in the optic tract [73]. In contrast, a more recent study
found no relationship between temporal RNFL thickness and potential markers of primary optic tract
damage using DTI, suggesting that there is a lack of axonal damage to the retinal ganglion cell axons
that form the optic tract [72]. However, it is possible that such a relationship was not observed in this
study because the correlation with the temporal RNFL thickness was not made specifically with the
ipsilateral optic tract, and instead included both tracts.
5. Thalamus
The thalamus, which contains the lateral geniculate nucleus, is a gray matter structure that
relays both motor and sensory signals to the brain; it may be affected in both MS and NMOSD [76].
Gray matter atrophy in the thalamus was found to be related to peripapillary and macular RNFL
thinning in MS [61,77]. An increased rate of GCL-IPL in MS was also correlated with an increased rate
of thalamic and brainstem atrophy over time [28]. There is currently a lack of studies assessing the
relationship between thalamic atrophy and retinal neuronal pathology in NMOSD.
6. Optic Radiation
The optic radiations are part of the posterior visual pathway, immediately anterior to primary
visual cortex. Lesions in the optic radiations may be both primary in nature, but also secondary
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to damage in surrounding brain regions [47]. Peripapillary RNFL thickness and macular volume
was associated with lesion volume, NAWM and abnormal DTI measurements in the optic radiations
of MS patients [47,60,72,77]. Similar associations were seen in a study looking at focal atrophy
in the optic radiations and RNFL thinning in early MS [78]. Whilst initial studies observed this
relationship in patients with or without a history of ON [47,77], more recent studies [60,78] found
that this relationship was significant only in MS patients without previous ON. Additionally, another
study found no correlation between DTI measures in the optic radiations and RNFL thickness in a
cohort of RRMS patients with a history of ON [49]. The significance of the relationship to RNFL in
MS patients with a history of ON may be masked by severe damage in the retina post-ON [60,78].
Likewise, the ganglion cell complex (GCC) thickness, which includes the RNFL, GCL and IPL, was
also significantly associated with abnormal DTI and increased lesion volume in the optic radiations
of MS patients without a history of ON [60]. Another study found a positive relationship between
retinal OCT parameters (peripapillary RNFL thickness, GCL, IPL, and TMV, although not INL) and
MWI of the optic radiations in a cohort including healthy controls, MS and NMOSD patients [79].
The authors did not find any relationship between OCT measures and lesion volume in the optic
radiations, unlike in previous work [60,78], but this may have been due to the small sample size
of the study [79]. The relationship between retinal and optic radiation degeneration most likely
involves both subclinical disease activity and possibly a common, as yet unknown, disease process
affecting both the anterior and posterior visual pathway. Another widely-discussed possibility is
trans-synaptic degeneration [28,60,77]. Many studies [60,77–79] have found an association between
axonal degeneration in the retina and brain in both MS and NMOSD patients independent of a
previous history of ON, providing further support for either subclinical disease activity or retrograde
trans-synaptic degeneration induced by lesions in the optic radiation of MS patients.
7. Visual Cortex
A positive relationship between peripapillary RNFL thickness and occipital gray matter thickness
has been documented in NMOSD patients [80]. This thinning seen in the pericalcarine cortex is
thought to be due to Wallerian degeneration, but it is also possible that subclinical disease activity
may be involved [80]. Similarly, in MS, the average RNFL thickness was significantly associated
with visual cortex volume in the primary (V1) and secondary (V2) visual cortices, independent of
factors such as ON [77]. However, in another study [60], GCC and RNFL were only associated with
V1 in MS patients with prior ON history, and not with secondary visual areas V2 or V5. Using MRS,
a decay in the absolute levels of NAA (a neuronal marker) in the visual cortex was observed to be
significantly correlated with decreasing peripapillary RNFL thickness and TMV in the overall MS
cohort, most strongly in patients without a history of ON [57,77]. Some authors have speculated that
since these relationships have been observed in patients without a history of ON, there is a possibility
of retrograde degeneration from the visual cortex to the retina [77]. One study found that BPF and
NAA in the visual cortex was independently associated with peripapillary RNFL thinning, suggesting
that further progressive neuronal atrophy is involved in the visual pathway beyond the diffuse global
neurodegeneration observed in MS [57]. The relationship seen between peripapillary RNFL and
cortical volume raises the possibility that this OCT measure of unmyelinated CNS axonal integrity may
be connected to gray matter atrophy in the brain via clinically relevant processes such as retrograde
degeneration [61].
8. Cerebellum, Brainstem and Deep Gray Matter
In RRMS, brainstem and cerebellar WM volume was correlated with peripapillary RNFL and
GCL-IPL thickness [40]. The rate of decrease in peripapillary RNFL thickness was also associated with
caudate and brainstem atrophy over time [28]. Macular RNFL and ONL (but not INL) thickness was
also related to caudate volume, specifically in MS subjects without ON history [40]. However, the
RNFL over the macula is relatively thin, and absent at the foveola, and thus a floor effect may affect
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our interpretation of the results seen [68]. ONL thickness was related to cerebellar WM volume in
RRMS eyes with prior ON, cortical GM volume in the secondary progressive MS cohort, and brainstem
volume in the PPMS cohort [40]. This relationship with the substructures of the brain suggests that the
ONL may reflect global neurodegeneration in MS [40].
9. Conclusions
A clear relationship exists between retinal pathology and both whole brain and regional brain
atrophy in MS and NMOSD. Whether this is the result of retrograde/anterograde degeneration or
subclinical disease activity is still uncertain. However, retinal, as well as brain, atrophy appears to occur
even in the absence of ON or other focal inflammatory episodes in MS and NMOSD, which may be
the result of as yet ill-defined primary retinal pathology. It is also possible that both OCT and MRI
are measuring a similar phenomenon of subclinical demyelination and axonal/neuronal degeneration.
OCT provides a localized measurement of retinal atrophy that may be reflective of brain pathology;
it may however be less informative, in that it is restricted to a discrete functional pathway (i.e., visual) and
thus less broadly representative of more widespread functional CNS damage. However, its convenience,
low cost and non-invasive nature makes it an attractive complement to MRI for patients.
Currently, the majority of the published reports are based on retrospective, exploratory studies.
Histological and animal studies are needed to confirm or to exclude the current assumptions regarding
the correlations observed between OCT and MRI on a sub-structural level. Future work should
consider correlations in the optic tract that are anterior to and including the lateral geniculate nucleus
as this is, to date, relatively unexplored. Additionally, relationships should further be assessed using
advanced imaging tools, such as MTI and MWI, and should include examination of all retinal layers
including the ONL or photoreceptor layer.
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